Safety of Sublingual dmLT for ETEC
NCT02052934
Completed
A Phase 1 dose escalating study of ETEC candidate vaccine to determine safety and immunogenicity of a multi-dose regimen in healthy adult volunteers. The study will be conducted at Cincinnati Children's Hospital Medical Center (CCHMC). The primary objectives assess the safety and tolerability of dmLT vaccine when administered in three doses sublingually over a range of dosages in healthy adult subjects. The secondary objectives assess long-term safety follow-up from immunization through Month 7... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
01/24/2019
Locations: Cincinnati Children's Hospital Medical Center - Gastroenterology, Hepatology and Nutrition, Cincinnati, Ohio
Conditions: Gastroenteritis Escherichia Coli
Register for Updates
CS DNA MVA Trial in Mampong, Ghana
NCT00377494
Withdrawn
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of 2 doses of a malaria vaccine (DNA) followed by a dose of another type of malaria vaccine (MVA) given as a "booster." Forty-eight adults in Ghana, ages 18-50 years, will participate for 17 months. They will be randomly assigned to 1 of 4 treatment groups. Group 1 will receive the DNA malaria vaccine at months 0 and 1, and the booster at month 7. Group 2 will receive a rabies vaccine at months 0 and 1, and an i... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/18/2019
Locations: Naval Medical Research Center, Silver Spring, Maryland +1 locations
Conditions: Plasmodium Falciparum Malaria
Register for Updates
Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission
NCT01349569
Completed
This research is being done to find out if the investigators can improve outcomes for multiple myeloma patients by giving a myeloma vaccine to patients who are already on lenalidomide (Revlimid) and in a near complete remission.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2019
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Multiple Myeloma
Register for Updates
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
NCT00224484
Completed
Main goal of this study is to compare the occurrence of serious adverse events (SAEs) between the herpes simplex (gD2-AS04) vaccine group and the Saline control group throughout the study period (up to month 12). The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Gender:
FEMALE
Ages:
Between 10 years and 17 years
Trial Updated:
01/03/2019
Locations: GSK Investigational Site, Birmingham, Alabama +151 locations
Conditions: Herpes Simplex
Register for Updates
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
NCT02914275
Completed
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 6 months through 59 months of age.
Gender:
ALL
Ages:
Between 6 months and 59 months
Trial Updated:
12/30/2018
Locations: Site 434, Birmingham, Alabama +38 locations
Conditions: Influenza, Human
Register for Updates
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
NCT01609998
Completed
This is a Phase I, dose escalation study in healthy adolescents and children (6-17 years) to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of the 2012/2013 seasonal influenza DNA vaccine (HA DNA) followed by licensed 2012/2013 TIV vaccine. The comparator groups will receive licensed 2012/2013 TIV as prime and boost. The hypothesis is that the 2012/2013 HA DNA prime-TIV boost regimen will be safe and result in a broader and more durable immune response than is obs... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
12/04/2018
Locations: Emory Children's Center, Atlanta, Georgia +4 locations
Conditions: Influenza
Register for Updates
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
NCT02052726
Completed
This study will investigate a clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine. Subjects will receive their vaccine doses at either months 0, 1, and 3 or days 1, 8, and 30. Subjects will be divided into 2 age groups (50-64 and 65-85 years of age). The study will assess how safe and tolerable the vaccine is, and also look at subjects' immune response to the vaccine.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
11/30/2018
Locations: Vince & Associates Clinical Research, Inc., Overland Park, Kansas +9 locations
Conditions: Clostridium Difficile
Register for Updates
Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients
NCT01493154
Terminated
This study will test the safety of an HPV DNA vaccine after it is injected into your muscle using an electroporation device (TriGridTM Delivery System made by Ichor Medical Systems), and will test the ability of the vaccine to help your body's immune system to recognize HPV-infected and associated cancer cells. In addition to giving the vaccine using an electroporation device, we are giving the vaccine in combination with an immunomodulatory agent to further enhance immune responses against HPV-... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/20/2018
Locations: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Head and Neck Cancer
Register for Updates
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
NCT03438344
Withdrawn
This randomized phase II trial studies how well multi-antigen cytomegalovirus (CMV)-modified vaccinia Ankara vaccine works in reducing CMV related complications in patients with blood cancer who are undergoing donor stem cell transplant. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2018
Locations: City of Hope Medical Center, Duarte, California +2 locations
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Bone Marrow Transplantation Recipient, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic Cell Transplantation Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Register for Updates
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
NCT00640861
Completed
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is most effective in treating breast cancer. PURPOSE: This randomized clinical trial is studying the side effects of three different vaccine therapies and comparing the vaccines to see how well they work in treating patients with previously treated stage II or stage III breast cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/29/2018
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Breast Cancer
Register for Updates
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
NCT03191383
Withdrawn
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the investigational GSK RSV vaccine in pregnant women aged 18 to 40 years and infants born to the vaccinated women
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
10/12/2018
Locations: GSK Investigational Site, Newton, Kansas +11 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Pilot Study of DRibble Vaccine for Prostate Cancer Patients
NCT02234921
Completed
This is a pilot study of the DRibble vaccine in patients with advanced prostate cancer.
Gender:
MALE
Ages:
All
Trial Updated:
10/09/2018
Locations: Providence Health & Services, Portland, Oregon
Conditions: Adenocarcinoma of the Prostate
Register for Updates